Pulmonary hypertension in systemic sclerosis: Bete noire no more?

Current Opinion in Rheumatology

Volumn 14, Issue 6, 2002, Pages 666-670

  Varga, John ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; GLUCOCORTICOID; ILOPROST; IMMUNOSUPPRESSIVE AGENT; INOTROPIC AGENT; OXYGEN; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; VASODILATOR AGENT;

ALLELE; ANTIBODY DETECTION; CELL DAMAGE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFECT; EDITORIAL; ELECTROCARDIOGRAM; ENDOTHELIUM CELL; FLUSHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFUSION PUMP; LUNG TRANSPLANTATION; PAIN; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SKIN MANIFESTATION; SYNCOPE; SYSTEMIC SCLEROSIS;

ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 0036838341     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200211000-00007     Document Type: Editorial

References (41)

1. Salerni R, Rodnan GP, Leon DF, et. al. L Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 1977, 86:394-399.
2. Ungerer RG, Tashkin DP, Furst D, et al.: Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983, 75(1):65-74.
3. Stupi AM, Steen VD, Owens GR, et al.: Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986, 29(4):515-524.
4. LeRoy EC: Pulmonary hypertension: the bete noire of the diffuse connective tissue diseases. Am J Med 1991, 90(5):539-540.
5. Altman RD, Medsger TA Jr, Bloch DA, et al.: Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991, 34(4):403-419.
6. Steen VD, Graham G, Conte C, et al.: Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992, 35(7):765-770.
7. Battle RW, Davitt MA, Cooper SM, et al.: Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996, 110(6):1515-1519.
8. Koh ET, Lee P, Gladman DD, et al.: Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996, 35:989-993.
9. MacGregor AJ, Canavan R, Knight C, et al.: Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology 2001, 40:453-459.
10. Yousem SA: The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 1990, 21:467-474.
11. Reveille JD, Fischbach M, McNearney T, et al.: Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001, 30(5):332-346.
12. Langevitz P, Buskila D, Gladman DD, et al.: HLA alleles in systemic sclerosis: association with pulmonary hypertension and outcome. Br J Rheumatol 1992, 31 (9):609-613.
13. Okano Y, Steen VD, Medsger TA Jr.: Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 1992, 35(1):95-100.
14. Tormey VJ, Bunn CC, Denton CP, et al.: Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology 2001, 40(10):1157-1162.
15. Giunta A, Tirri E, Maione S, et al.: Right ventricular diastolic abnormalities in systemic sclerosis: relation to left ventricular involvement and pulmonary hypertension. Ann Rheum Dis 2000, 59(2):94-98.
16. Barst RJ, Rubin LJ, Long WA, et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 334(5):296-302.
17. Rich S, Kaufmann E, Levy PS: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992, 327(2):76-81.
18. Kharitonov SA, Cailes JB, Black CM, et al.: Decreased nitric oxide in the exhaled air of patients with SSc with pulmonary hypertension. Thorax 1997, 52(12):1051-1059.
19. Cailes J, Winter S, du Bois RM, et al.: Defective endothelially mediated pulmonary vasodilation in systemic sclerosis. Chest 1998, 114:178-184.
20. Machado RD, Pauciulo MW, Thomson JR, et al.: BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001, 68:92-102.
21. Lane KB, Machado RD, Pauciulo MW, et al.: Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000, 26:81-84.
22. Johnson R, Tew M, Arnett FC: The genetics of systemic sclerosis. Current Rheum Reports 2002, 4:99-107.
23. al-Sabbagh MR, Steen VD, Zee BC, et al.: Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study. J Rheumatol 1989, 16(8):1038-1042.
24. Miyauchi T, Masaki T: Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol.
25. Shi-Wen X, Denton CP, Dashwood MR, et al.: Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001, 116(3):417-425.
26. Kadono T, Kikuchi K, Sato S, et al.: Elevated plasma endothelin levels in systemic sclerosis. Arch Dermatol Res 1995, 287(5):439-442.
27. Vancheeswaran R, Magoulas T, Efrat G, et al.: Circulating endothelin-1 levels in systemic sclerosis subsets: a marker of fibrosis or vascular dysfunction? J Rheumatol 1994, 21(10):1838-1844.
28. Reichenberger F, Schauer J, Kellner K, et al.: Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases. Lung 2001, 179(3):163-174.
29. Abraham DJ, Vancheeswaran R, Dashwood MR, et al.: Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997, 151 (3):831-841.
30. Morgan JM, Griffiths M, du Bois RM, et al.: Hypoxic pulmonary vasoconstriction in systemic sclerosis and primary pulmonary hypertension. Chest 1991, 99(3):551-556.
31. Rubin LJ, Mendoza J, Hood M, et al.: Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 1990, 112(7):485-491.
32. Barst RJ, Rubin LJ, McGoon MD, et al.: Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994, 121(6):409-415.
33. Badesch DB, Tapson VF, McGoon MD, et al.: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000, 132(6):425-434.
34. Klings ES, Hill NS, leong MH, Simms RW, Korn JH, Farber HW. Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin). Arthritis Rheum 1999, 42(12):2638-2645.
35. Farber HW, Graven KK, Kokolski G, et al.: Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma. J Rheumatol 1999, 26(5):1195-1196.
36. Olschewski H, Simonneau G, Galie N, et al.: Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002, 347:322-329.
37. Rubin LJ, Badesch DB, Barst RJ, et al.: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896-903.
38. Pasque MK, Trulock EP, Cooper JD, et al.: Single lung transplantation for pulmonary hypertension: single institution experience in 34 patients. Circulation 1995, 92(8):2252-2258.
39. Pigula FA, Griffith BP, Zenati MA, et al.: Lung transplantation for respiratory failure resulting from systemic disease. Ann Thorac Surg 1997, 64:1630-1634.
40. Rosas V, Conte JV, Yang SC, et al.: Lung transplantation and systemic sclerosis. Ann Transplant 2000, 5(3):38-43.
41. Allcock RJ, O'Sullivan JJ, Corris PA: Palliation of systemic sclerosis-associated pulmonary hypertension by atrial septostomy. Arthritis Rheum 2001, 44(7):1660-1662.